Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Roche To Acquire France’s Trophos
by Ann M. Thayer
January 26, 2015
| A version of this story appeared in
Volume 93, Issue 4
Roche has agreed to pay $140 million up front and up to $400 million more in milestone payments to acquire Trophos, a biotech firm based in Marseille, France. Along with venture capitalists, investors in the 16-year-old company have included the French Muscular Dystrophy Association. Trophos specializes in cholesterol-oxime chemistry. Designed to protect motor nerve cells, its lead compound, olesoxime, is in Phase II clinical trials against spinal muscular atrophy, a rare genetic disease. U.S. and European regulators have given orphan drug designation to olesoxime.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X